Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference from February 24-26, 2021. The management team will join a fireside chat on February 24 at 3:40 p.m. ET. A live webcast will be available for viewing on Avadel's website and will remain accessible for 90 days. The company is focused on FT218, an investigational sodium oxybate formulation aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, and has submitted a New Drug Application to the FDA.

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24^th to 26^th.

Fireside Chat Details:
Event:	SVB Leerink 10th Annual Global Healthcare Conference
Time and Date:	3:40 p.m. ET on Wednesday, February 24th
Webcast:	A live webcast of this event, as well as an archived recording, will be available at (click here), as well as on Avadel’s website, www.avadel.com, for 90 days from being made available.

About FT218
FT218 is an investigational, once-nightly formulation of sodium oxybate that includes Avadel’s MicroPump™ controlled-release (CR) technology. In December 2020, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.

About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Contacts:
	Tom McHugh
	Chief Financial Officer
	Phone: (636) 449-1843
	Email: tmchugh@avadel.com
	Tim McCarthy
	LifeSci Advisors, LLC
	Phone: (212) 915-2564
	Email: tim@lifesciadvisors.com

FAQ

What is Avadel Pharmaceuticals' focus in the stock market?

Avadel Pharmaceuticals (Nasdaq: AVDL) focuses on developing FT218, a treatment for excessive daytime sleepiness and cataplexy in adults with narcolepsy.

When is Avadel Pharmaceuticals participating in the SVB Leerink Global Healthcare Conference?

Avadel Pharmaceuticals will participate in the SVB Leerink Global Healthcare Conference on February 24, 2021.

What time is Avadel Pharmaceuticals' fireside chat during the conference?

The fireside chat is scheduled for 3:40 p.m. ET on February 24, 2021.

How can I access the webcast of Avadel Pharmaceuticals' fireside chat?

The webcast of Avadel Pharmaceuticals' fireside chat can be accessed through their website and will be available for 90 days.

What is FT218 and why is it significant for Avadel Pharmaceuticals?

FT218 is an investigational, once-nightly sodium oxybate formulation aimed at treating narcolepsy, and its FDA approval is critical for Avadel's portfolio.